Methylprednisolone sodium succinate - Nihon Pharmaceutical
Alternative Names: NPB-01-MELatest Information Update: 27 Jan 2022
At a glance
- Originator Nihon Pharmaceutical
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antirheumatics; Corticosteroids
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Encephalitis
Most Recent Events
- 05 Jan 2022 Preclinical trials in Encephalitis in Japan (unspecified route), prior to January 2022 (NCT05177939)
- 05 Jan 2022 Nihon Pharmaceutical plans a phase III trial for autoimmune Encephalitis (In adolescents, In adults, In the elderly, Treatment-experienced) (IV), in February 2022 (NCT05177939)